BridgeBio Pharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenues of $120.7 million for the quarter, a substantial increase from $2.7 million in the same period last year. This growth was primarily driven by net product revenue of $108.1 million from its recently launched product, Attruby, which received FDA approval in November 2024. For the nine months ended September 30, 2025, total revenues reached $347.9 million, compared to $216.0 million in the prior year, reflecting a notable increase in both product sales and royalty revenues.
Operating expenses for the third quarter totaled $265.9 million, up from $194.5 million in the same quarter of 2024. This increase was largely attributed to higher selling, general, and administrative expenses, which rose to $137.6 million from $68.8 million, as the company ramped up its commercial activities. Research and development expenses decreased slightly to $112.9 million from $120.4 million year-over-year, indicating a strategic reprioritization of R&D efforts. The net loss for the quarter was $184.9 million, compared to a loss of $164.3 million in the prior year, with a net loss attributable to common stockholders of $182.7 million.
In terms of strategic developments, BridgeBio has made significant strides in its product pipeline. The company has received multiple regulatory approvals for its products, including Beyonttra in the EU and Japan, which are expected to contribute to future revenue streams. Additionally, BridgeBio entered into a Royalty Interest Purchase and Sale Agreement, securing $300 million in cash, which will support its ongoing operations and product development. The company also reported a decrease in its cash and cash equivalents to $643.0 million as of September 30, 2025, down from $681.1 million at the end of 2024.
Operationally, BridgeBio has focused on expanding its market presence and enhancing its product offerings. The company reported a significant increase in customer engagement, with net product revenue from Attruby indicating strong market adoption. The company’s workforce has also grown, reflecting its commitment to supporting its commercial launch and ongoing development programs. Looking ahead, BridgeBio anticipates continued investment in its product pipeline and commercialization efforts, although it expects to incur further operating losses as it scales its operations.
Overall, BridgeBio's financial performance in the third quarter of 2025 highlights its successful transition to a commercial-stage biopharmaceutical company, driven by the launch of Attruby and strategic partnerships. The company remains focused on advancing its product candidates while managing its operational costs and exploring additional funding opportunities to support its growth trajectory.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases. Its core products include Attruby/Beyonttra, an oral therapy for transthyretin amyloid cardiomyopathy, and late-stage clinical candidates targeting achondroplasia, autosomal dominant hypocalcemia, and limb girdle muscular dystrophy. BridgeBio leverages genetic insights and innovative drug platforms to address high unmet medical needs, serving patients through regulatory approvals and strategic partnerships.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.